Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RGNX

+ Watchlist+ Portfolio

REGENXBIO Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$7.26
52-Week Range
$5.46 – $16.19
Market Cap
$474.76M
P/E (TTM)
—
EPS (TTM)
-3.20
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.21
PEG Ratio
—
Return on Equity
-113.24%
Return on Assets
-23.37%
Gross Margin
-64.53%
Operating Margin
-120.39%
Profit Margin
-113.85%
Current Ratio
4.74
Debt/Equity
1.70
Total Debt
$252.22M
Free Cash Flow
$-128.85M
Revenue Growth
-69.20%
Earnings Growth
—
Enterprise Value
$481.30M

Market Snapshot

About

REGENXBIO is a clinical-stage biotechnology company developing gene therapies using its proprietary adeno-associated virus (AAV) platform. The company advances treatments for genetic diseases affecting the eye, liver, and central nervous system. REGENXBIO also licenses its NAV Technology Platform to other biotech and pharmaceutical companies, creating a dual revenue model from internal development and technology partnerships.